How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Want to cut your energy bills? Here’s how five experts are doing it 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
TUSTIN, Calif., March 07, 2016 -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2016 to holders of record at the close of business on March 18, 2016.
The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from January 1, 2016 through March 31, 2016. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "PPHMP".
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics to stimulate the body's immune system to fight cancer. The company is focused on evaluating its lead immunotherapy candidate, bavituximab, in combination with a range of novel immuno-oncology (I-O) agents for the treatment of various cancers. One specific component of this I-O combination strategy includes a planned clinical trial of bavituximab in combination with durvalumab, AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, under a clinical collaboration.
In addition to its drug development programs, Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.
Contacts: Jay Carlson Peregrine Pharmaceuticals, Inc. (800) 987-8256 [email protected] Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
